⚕ GalenOps field
←

SITE010-0381

completed

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE010 (ESP) · Dr. Silva
consented 2023-05-29

AEs
8
Serious
0
Dropout signal
–

Adverse events

mild assessed

Grade 1 Colitis — outcome: RECOVERED/RESOLVED; onset 2023-07-02 (study day 23); relationship: Y

moderate assessed

Grade 2 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-07-12 (study day 33); relationship: N

moderate assessed

Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-07-23 (study day 44); relationship: not assessed

moderate assessed

Grade 2 Anaemia — outcome: RECOVERED/RESOLVED; onset 2023-07-23 (study day 44); relationship: N

mild assessed

Grade 1 Stomatitis — outcome: RECOVERED/RESOLVED; onset 2023-08-21 (study day 73); relationship: not assessed

mild assessed

Grade 1 Rash — outcome: RECOVERED/RESOLVED; onset 2023-08-24 (study day 76); relationship: not assessed

mild assessed

Grade 1 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2023-08-24 (study day 76); relationship: Y

moderate assessed

Grade 2 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-09-13 (study day 96); relationship: not assessed

Data queries

No data queries.